Products

Brcaone 150mg Tablet (Olaparib): Precision PARP Inhibitor for Targeted Oncology Care Brcaone 150mg Tablet is a specialized, targeted anti-cancer medication featuring the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Bresure Care, Brcaone 150mg represents a breakthrough in precision medicine, specifically engineered to exploit genetic vulnerabilities in cancer cells—particularly those with BRCA mutations—to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Brcaone 150mg is utilized globally for the management of advanced malignancies, specifically targeting cancers associated with BRCA1/BRCA2 gene mutations and homologous recombination repair (HRR) deficiencies: Advanced Ovarian Cancer: Used as a maintenance treatment for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. HER2-Negative Metastatic Breast Cancer: Indicated for the treatment of adult patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy.Metastatic Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Metastatic Castration-Resistant Prostate Cancer (mCRPC): Prescribed for patients with specific HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone. Mechanism of Action: How Brcaone 150mg Works Enzyme Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Brcaone binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during cell replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA1/2 mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Selective Targeting: Because healthy cells have intact alternative DNA repair pathways, they are significantly less affected by Brcaone than cancerous ones, reducing systemic damage. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300mg (two 150mg tablets) taken twice daily, totaling 600mg per day. Method of Intake: Tablets must be swallowed whole with water. They should not be chewed, crushed, dissolved, or divided. Timing: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart to maintain steady therapeutic levels. Clinical Adjustments: Dosage may be modified by an oncologist based on individual patient tolerance, renal function, or to manage specific adverse reactions. Safety Profile and Professional Monitoring Hematological Monitoring: Common side effects include anemia, neutropenia (low white blood cells), and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are required before and during treatment. Gastrointestinal Support: Nausea, vomiting, and diarrhea are frequently reported. These are managed with supportive care and adequate hydration. Respiratory Vigilance: Patients should report any new or worsening shortness of breath or cough, as inflammation of the lungs (pneumonitis) can occur in rare cases. Embryo-Fetal Toxicity: Olaparib can cause fetal harm. Effective contraception is mandatory for both male and female patients of reproductive potential during treatment. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep tablets in the original container to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the tablets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celnalid 5mg Capsule (Lenalidomide): Low-Dose Precision Immunomodulatory Therapy: Celnalid 5mg capsule is a specialized anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a critical dosage form used primarily for maintenance therapy, dose tapering, and patients requiring renal dose adjustments. Manufactured by Celon Laboratories Pvt. Ltd., Celnalid 5mg is an essential component in the long-term management of hematological malignancies, providing a balance between therapeutic efficacy and manageable toxicity. Therapeutic Indications and Clinical Usage Celnalid 5 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5 mg dose is often used as a long-term maintenance strategy to prevent disease relapse. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Renal Dose Adjustments: For patients with moderate to severe renal impairment, the 5 mg capsule allows for precise dosing to maintain efficacy while reducing the risk of systemic toxicity. Relapsed/Refractory Lymphoma: Used in combination with other agents for patients with Mantle Cell Lymphoma (MCL) or Follicular Lymphoma who require a lower starting dose or a dose reduction. Mechanism of Action: How Celnalid 5 mg Works Even at a lower 5 mg concentration, Lenalidomide exerts a potent multi-pathway biological effect: Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors (Ikaros and Aiolos) necessary for cancer cell survival. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors (like VEGF), preventing the tumor from forming the new blood vessels it needs to grow. Immune Surveillance: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to find and destroy residual cancer cells. Cytokine Modulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$, which otherwise support the survival of malignant cells in the bone marrow microenvironment. Dosage and Administration Guidelines Maintenance Dosing: In maintenance settings, Celnalid 5 mg is often taken once daily on a continuous basis or following a “21 days on, 7 days off“ cycle. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Escalation/De-escalation: The 5 mg strength provides oncologists with the flexibility to titrate the dose upward as tolerated or downward to manage hematological toxicities. Safety Profile and Clinical Monitoring Low-dose therapy still requires vigilant professional oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia and thrombocytopenia, though these are typically less frequent at the 5 mg level than at higher doses. Thromboembolism Prophylaxis: Even at 5mg, there remains a risk of blood clots (DVT/PE). Anticoagulant therapy (e.g., Aspirin) is frequently continued during maintenance. Embryo-Fetal Toxicity (REMS): Lenalidomide remains a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of dosage. General Side Effects: Patients may experience mild fatigue, diarrhea, or skin rashes. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep the capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celnalid 25mg Capsule (Lenalidomide): High-Potency Immunotherapy for Advanced Oncology Celnalid 25 mg Capsule is a high-strength anti-cancer medication featuring the active pharmaceutical ingredient lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 25 mg strength is primarily utilized during the intensive induction phase of treatment for various hematological malignancies. Manufactured by Celon Laboratories Pvt. Ltd., Celnalid 25mg is a critical therapeutic intervention designed to disrupt cancer cell proliferation while enlisting the body's natural immune defenses. Therapeutic Indications and Clinical Usage Celnalid 25 mg is utilized across major international oncology protocols for Multiple Myeloma (MM): Used as a first-line therapy (typically in combination with Dexamethasone) for newly diagnosed patients and as a primary treatment for relapsed or refractory cases. Mantle Cell Lymphoma (MCL): Indicated for patients whose disease has progressed or relapsed after at least two prior therapies, including one involving a proteasome inhibitor. Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Follicular Lymphoma (FL): Often used in combination with Rituximab for adult patients previously treated for follicular or marginal zone lymphoma.Mechanism of Action: How Celnalid 25mg Works The efficacy of Celnalid 25 mg stems from its multi-pronged biological approach: Direct Tumoricidal Effect: It induces cell cycle arrest and triggers apoptosis (programmed cell death) specifically in malignant hematopoietic cells. Immune System Enhancement: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body’s innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply, effectively “starving“ the tumor. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which otherwise promote the growth of myeloma cells in the bone marrow. Dosage and Administration Guidelines Intensive Dosing: The 25 mg strength is typically the starting dose for many multiple myeloma regimens, often taken once daily on Days 1–21 of a 28-day cycle. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Timing: Can be taken with or without food, but should be taken at a consistent time each day to maintain therapeutic plasma levels. Dose Adjustments: Physicians may reduce the dose from 25 mg to lower strengths (15 mg, 10 mg, or 5 mg) based on patient tolerance, renal function, or during the maintenance phase of therapy. Safety Profile and Clinical Monitoring Due to its high potency, Celnalid 25mg requires strict medical supervision: Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed blood thinners (anticoagulants) concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should handle the capsules with care; avoid skin contact if a capsule is accidentally broken. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celomide 25mg Capsule (Lenalidomide): High-Potency Immunomodulatory Therapy for Oncology CareCelomide 25mg Capsule is a high-strength anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. As a primary immunomodulatory imide drug (IMiD), the 25 mg strength represents the intensive induction phase dosage used globally to treat aggressive hematological malignancies. Manufactured by Celon Laboratories Pvt. Ltd., Celomide 25mg is a cornerstone in precision oncology, designed to disrupt cancer cell proliferation while enlisting the body's natural immune defenses. Therapeutic Indications and Clinical Usage Celomide 25 mg is utilized across major international oncology protocols for: Multiple Myeloma (MM): Used as first-line therapy (in combination with Dexamethasone) for newly diagnosed patients and as a primary treatment for relapsed or refractory cases. Mantle Cell Lymphoma (MCL): Indicated for patients whose disease has progressed or relapsed after at least two prior therapies. Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Follicular Lymphoma (FL): Often used in combination with Rituximab for previously treated adult patients.Mechanism of Action: How Celomide 25mg WorksThe efficacy of Celomide 25mg stems from its multi-pronged biological approach:Direct Tumoricidal Effect: It induces cell cycle arrest and triggers apoptosis (programmed cell death) specifically in malignant hematopoietic cells.Immune System Enhancement: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body’s innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply, effectively “starving“ the tumor. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which otherwise promote the growth of myeloma cells. Dosage and Administration Guidelines Intensive Dosing: The 25 mg strength is typically the starting dose for many multiple myeloma regimens, often taken once daily on Days 1–21 of a 28-day cycle. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Timing: Can be taken with or without food, but should be taken at a consistent time each day to maintain therapeutic plasma levels. Dose Adjustments: Physicians may reduce the dose from 25 mg to lower strengths (15 mg, 10 mg, or 5 mg) based on patient tolerance, renal function, or during the maintenance phase.Safety Profile and Clinical Monitoring Due to its high potency, Celomide 25mg requires strict medical supervision: Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed blood thinners (anticoagulants) concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should handle the capsules with care; avoid skin contact if a capsule is accidentally broken. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celomide 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Malignancies Celomide 10mg Capsule is a high-potency anti-cancer medication containing the active pharmaceutical ingredient Lenalidomide. As a leading immunomodulatory imide drug (IMiD), Celomide 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Celon Laboratories Pvt. Ltd., a premier specialty biopharmaceutical company, Celomide is recognized for its high efficacy in modulating the immune system to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Celomide 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed Multiple Myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Celomide 10mg Works Celomide exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance and clinical response. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Celomide 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Laviat 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Malignancies Laviat 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Laviat 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Indus (Fresenius Kabi), a global leader in high-quality pharmaceuticals, Laviat 10mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Laviat 10 mg is a cornerstone in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed Multiple Myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Laviat 10mg Works Laviat exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Laviat 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenakast 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Malignancies. Lenakast 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenakast 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Aprazer Healthcare, it is recognized for its high efficacy in modulating the immune system to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Lenakast 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed Multiple Myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenakast 10mg Works Lenakast exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenakast 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenangio 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Malignancies. Lenangio 10 mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenangio 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Dr. Reddy’s Laboratories, a global leader in high-quality pharmaceuticals, Lenangio 10mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lenangio 10 mg is a cornerstone in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed multiple myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenangio 10mg Works Lenangio exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenangio 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lendomy 10mg Capsule (Lenalidomide): Advanced Immunomodulatory Therapy for Hematological Cancers Lendomy 10 mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lendomy 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Mylan (Viatris), a global leader in high-quality pharmaceuticals, Lendomy 10mg offers a targeted approach to inhibiting tumor growth while stimulating the body's natural immune response. Therapeutic Indications and Clinical Usage Lendomy 10 mg is a cornerstone in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed multiple myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lendomy 10mg Works Lendomy exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lendomy 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tukavo 150mg Tablet (Tucatinib): Advanced HER2-Specific Tyrosine Kinase Inhibitor Tukavo 150 mg Tablet is a highly specialized oral antineoplastic agent containing the active ingredient Tucatinib. Developed as a next-generation Tyrosine Kinase Inhibitor (TKI), Tukavo is specifically engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2). It has become a cornerstone in the treatment of advanced HER2-positive breast cancers, offering new hope for patients, including those with difficult-to-treat brain metastases. Therapeutic Indications and Clinical Usage Tukavo 150 mg is utilized globally in advanced oncology settings for: HER2-Positive Metastatic Breast Cancer: Indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It is typically used in a triple-combination regimen with Trastuzumab and Capecitabine. Brain Metastases Management: Tukavo is uniquely effective because it can cross the blood-brain barrier. It is indicated for patients with or without brain metastases who have received one or more prior anti-HER2-based regimens. RAS Wild-Type Colorectal Cancer: In specific regulatory jurisdictions, it is used in combination with Trastuzumab for adult patients with HER2-positive metastatic colorectal cancer that has progressed after standard chemotherapy. Mechanism of Action: How Tukavo 150mg Works Tukavo works through a highly selective process of intracellular signaling blockade: Selective HER2 Inhibition: Unlike older TKIs that target multiple receptors, Tucatinib is highly selective for the HER2 protein. This selectivity helps minimize “off-target“ side effects like severe skin rashes or diarrhea associated with EGFR inhibition. Phosphorylation Blockade: By binding to the internal domain of the HER2 receptor, it prevents the phosphorylation process. This effectively shuts down the downstream signaling pathways (like MAPK and PI3K/Akt) that tell the cancer cell to multiply. Synergistic Effect: When used with Trastuzumab (which binds to the outside of the cell), Tukavo provides a “dual blockade,“ attacking the HER2 signaling from both the inside and the outside of the cancer cell. Blood-Brain Barrier Penetration: Its small molecular structure allows it to reach the central nervous system, making it a vital tool for treating cancer that has spread to the brain. Dosage and Administration Guidelines Standard Dosage: The recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily. Administration: Tablets must be swallowed whole. Do not chew, crush, or break the tablets. Consistency: Can be taken with or without food. It is best to take doses approximately 12 hours apart at the same time each day. Missed Dose: If a dose is missed or vomited, the patient should skip that dose and take the next one at the regularly scheduled time. Safety Profile and Professional Monitoring Treatment with Tukavo 150 mg requires close medical supervision: 1. Hepatotoxicity Monitoring Tukavo can affect liver function. Regular liver function tests (ALT, AST, and Bilirubin) are mandatory before starting treatment and every three weeks during therapy. 2. Gastrointestinal Support Diarrhea is a common side effect. Patients should be prepared with anti-diarrheal medications (like loperamide) and maintain high fluid intake. 3. General Side Effects Other commonly reported symptoms include fatigue, nausea, vomiting, stomatitis (mouth sores), and “hand-foot syndrome“ (redness or swelling of the palms and soles). 4. Embryo-Fetal Toxicity Tucatinib can cause fetal harm. Effective contraception is required for females of reproductive potential and their male partners during treatment and for at least one week after the final dose. Storage and Global Handling Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Original Packaging: Keep the tablets in their original container with the desiccant to protect them from moisture. Handling: Dispose of any unused Tukavo 3 months after opening the bottle. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Olpaza 150mg Tablet (Olaparib): Advanced PARP Inhibitor for Targeted Cancer Therapy Olpaza 150mg Tablet is a specialized, targeted anti-cancer medication containing the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Intas Pharmaceuticals Ltd., Olpaza 150mg represents a breakthrough in precision medicine, specifically designed to exploit genetic vulnerabilities in cancer cells to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Olpaza 150mg is utilized globally for the management of advanced malignancies, particularly those associated with BRCA1/BRCA2 gene mutations: Ovarian Cancer: Used as maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who are in complete or partial response to first-line platinum-based chemotherapy. Breast Cancer: Indicated for the treatment of gBRCA-mutated, HER2-negative metastatic breast cancer in patients previously treated with chemotherapy. Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line platinum-based chemotherapy. Prostate Cancer: Indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations. Mechanism of Action: How Olpaza 150mg Works Olpaza works by specifically targeting the DNA repair machinery within cancer cells: PARP Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Olpaza binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Sparing Healthy Cells: Because normal cells have intact alternative DNA repair pathways, they are significantly less affected by Olpaza than cancerous ones. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300 mg (two 150 mg tablets) taken twice daily, totaling 600 mg per day. Administration: Tablets must be swallowed whole with water and should not be chewed, crushed, or dissolved. Flexibility: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart at the same time each day. Dose Adjustments: Oncologists may modify the dosage based on individual patient tolerance, renal function, or the occurrence of specific side effects. Safety Profile and Side Effect Management As a potent targeted therapy, Olpaza 150mg requires professional clinical monitoring: 1. Hematological Monitoring Common side effects include anemia, neutropenia (low white blood cell count), and thrombocytopenia (low platelet count). Regular blood tests (CBC) are required before and during treatment. 2. Gastrointestinal Support Nausea, vomiting, and diarrhea are frequently reported. These are often managed with anti-emetic medications and by maintaining adequate hydration (8–10 glasses of water daily). 3. Respiratory Vigilance While rare, inflammation of the lungs (pneumonitis) can occur. Patients should report any new or worsening shortness of breath or cough immediately. 4. Embryo-Fetal Toxicity Olaparib can cause fetal harm. Effective contraception is mandatory for both female and male patients of reproductive potential during and for several months after the final dose. Storage and Handling Temperature: Store below 30°C in a dry place. Protection: Keep the bottle tightly closed and away from direct sunlight and moisture. Safety: Store out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Lenid 10mg Capsule (Lenalidomide): Precision Immunotherapy for Hematological Malignancies Lenid 10mg Capsule is a high-potency anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), Lenid 10mg is a critical therapeutic agent used globally to treat various forms of blood and bone marrow cancers. Manufactured by Natco Pharma Ltd., a global pioneer in oncology generics, Lenid is recognized for its high efficacy in modulating the immune response to identify and destroy malignant cells while inhibiting tumor growth. Therapeutic Indications and Clinical Usage Lenid 10mg is a primary choice in international oncology protocols for: Multiple Myeloma (MM): Indicated for adult patients with newly diagnosed multiple myeloma, often used in combination with dexamethasone. It is also a gold-standard choice for maintenance therapy following autologous stem cell transplantation (ASCT). Myelodysplastic Syndromes (MDS): Specifically used for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma (FL): Used in combination with rituximab for previously treated adult patients with follicular or marginal zone lymphoma. Mechanism of Action: How Lenid 10mg Works Lenid exerts its therapeutic effects through a multi-dimensional biological approach: Immune System Augmentation: It enhances the activity of T-cells and Natural Killer (NK) cells, empowering the body's natural defenses to destroy cancer cells more aggressively. Direct Antitumor Activity: It induces cell cycle arrest and triggers apoptosis (programmed cell death) in malignant hematopoietic cells. Anti-Angiogenesis: It blocks the formation of new blood vessels that tumors rely on for oxygen and nutrients, effectively “starving“ the tumor. Cytokine Regulation: It inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to fuel the proliferation of myeloma cells. Dosage and Administration Guidelines Dosing Schedule: Usually administered in 28-day cycles. The 10 mg strength is frequently utilized for maintenance therapy or adjusted dosing based on patient tolerance and renal function. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at approximately the same time each day to maintain steady therapeutic levels. Clinical Monitoring: Dosage adjustments are strictly managed by oncologists based on renal function and blood cell counts. Safety Profile and Side Effect Management As a potent targeted therapy, Lenid 10mg requires vigilant professional oversight: 1. Hematological Vigilance The most common side effects include neutropenia (low white blood cells) and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are mandatory to monitor for infection or bleeding risks. 2. Thromboembolism Prophylaxis There is an increased risk of blood clots (DVT or Pulmonary Embolism). Patients are typically prescribed prophylactic anticoagulants (like aspirin or heparin) concurrently. 3. Embryo-Fetal Toxicity (REMS) Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients of reproductive potential. 4. General Side Effects Commonly reported symptoms include fatigue, diarrhea, muscle cramps, and skin rashes. These are usually managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should avoid direct skin contact with the capsules. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383